BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rich N, Singal AG. Hepatocellular carcinoma tumour markers: current role and expectations. Best Pract Res Clin Gastroenterol. 2014;28:843-853. [PMID: 25260312 DOI: 10.1016/j.bpg.2014.07.018] [Cited by in Crossref: 59] [Cited by in F6Publishing: 63] [Article Influence: 7.4] [Reference Citation Analysis]
Number Citing Articles
1 Martini A, Gallotta A, Pontisso P, Fassina G. Clinical applications of squamous cell carcinoma antigen-immunoglobulins M to monitor chronic hepatitis C. World J Hepatol 2015; 7(29): 2913-2919 [PMID: 26689503 DOI: 10.4254/wjh.v7.i29.2913] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
2 Vedarethinam V, Dhanaraj K, Ilavenil S, Arasu MV, Choi KC, Al-Dhabi NA, Srisesharam S, Lee KD, Kim da H, Dhanapal T, Sivanesan R, Choi HS, Kim YO. Antitumor Effect of the Mannich Base(1,3-bis-((3-Hydroxynaphthalen-2-yl)phenylmethyl)urea) on Hepatocellular Carcinoma. Molecules 2016;21:E632. [PMID: 27187346 DOI: 10.3390/molecules21050632] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
3 Xue F, Shi S, Zhang Z, Xu C, Zheng J, Qin T, Qian Z, Zhao X, Tong Y, Xia L, Xia Q. Application of a novel liquid biopsy in patients with hepatocellular carcinoma undergoing liver transplantation. Oncol Lett 2018;15:5481-8. [PMID: 29552189 DOI: 10.3892/ol.2018.8019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
4 Chikhale M, Toi PC, Siddaraju N, Ananthakrishnan R. The strength of cytomorphology and efficacy of immuno-cytochemistry in distinguishing hepatocellular carcinoma from its mimics on fine-needle aspiration cytology. Diagn Cytopathol 2021;49:864-75. [PMID: 33929782 DOI: 10.1002/dc.24759] [Reference Citation Analysis]
5 Mocan T, Simão AL, Castro RE, Rodrigues CMP, Słomka A, Wang B, Strassburg C, Wöhler A, Willms AG, Kornek M. Liquid Biopsies in Hepatocellular Carcinoma: Are We Winning? J Clin Med 2020;9:E1541. [PMID: 32443747 DOI: 10.3390/jcm9051541] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
6 Beebe SJ. Hepatocellular carcinoma ablation and possible immunity in the age of nanosecond pulsed electric fields. J Hepatocell Carcinoma 2015;2:49-55. [PMID: 27508194 DOI: 10.2147/JHC.S83941] [Reference Citation Analysis]
7 Chinen AB, Guan CM, Ferrer JR, Barnaby SN, Merkel TJ, Mirkin CA. Nanoparticle Probes for the Detection of Cancer Biomarkers, Cells, and Tissues by Fluorescence. Chem Rev 2015;115:10530-74. [PMID: 26313138 DOI: 10.1021/acs.chemrev.5b00321] [Cited by in Crossref: 629] [Cited by in F6Publishing: 507] [Article Influence: 89.9] [Reference Citation Analysis]
8 Hoskins B, Wasuwanich P, Scheimann AO, Karnsakul W. Screening strategy for gastrointestinal and hepatopancreatobiliary cancers in cystic fibrosis. World J Gastrointest Oncol 2021; 13(9): 1121-1131 [PMID: 34616517 DOI: 10.4251/wjgo.v13.i9.1121] [Reference Citation Analysis]
9 Patel N, Yopp AC, Singal AG. Diagnostic delays are common among patients with hepatocellular carcinoma. J Natl Compr Canc Netw 2015;13:543-9. [PMID: 25964640 DOI: 10.6004/jnccn.2015.0074] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
10 Sun J, Wei X, Xu L. Upregulation of lncRNA Sox2ot indicates a poor prognosis for patients with hepatocellular carcinoma and promotes cell invasion. Oncol Lett 2018;16:1189-95. [PMID: 29963193 DOI: 10.3892/ol.2018.8725] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
11 Sumi A, Akiba J, Ogasawara S, Nakayama M, Nomura Y, Yasumoto M, Sanada S, Nakashima O, Abe T, Yano H. Des-γ-carboxyprothrombin (DCP) and NX-DCP expressions and their relationship with clinicopathological features in hepatocellular carcinoma. PLoS One 2015;10:e0118452. [PMID: 25739032 DOI: 10.1371/journal.pone.0118452] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
12 Sun J, Zhao J, Wang L, Li H, Yang F, Yang X. Inner Filter Effect-Based Sensor for Horseradish Peroxidase and Its Application to Fluorescence Immunoassay. ACS Sens 2018;3:183-90. [PMID: 29260859 DOI: 10.1021/acssensors.7b00830] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 10.5] [Reference Citation Analysis]
13 Qu Z, Yuan CH, Yin CQ, Guan Q, Chen H, Wang FB. Meta-analysis of the prognostic value of abnormally expressed lncRNAs in hepatocellular carcinoma. Onco Targets Ther. 2016;9:5143-5152. [PMID: 27574455 DOI: 10.2147/ott] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
14 Wang K, Bai Y, Chen S, Huang J, Yuan J, Chen W, Yao P, Miao X, Wang Y, Liang Y, Zhang X, He M, Yang H, Guo H, Wei S. Genetic correction of serum AFP level improves risk prediction of primary hepatocellular carcinoma in the Dongfeng-Tongji cohort study. Cancer Med 2018;7:2691-8. [PMID: 29696820 DOI: 10.1002/cam4.1481] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
15 Yin CQ, Yuan CH, Qu Z, Guan Q, Chen H, Wang FB. Liquid Biopsy of Hepatocellular Carcinoma: Circulating Tumor-Derived Biomarkers. Dis Markers. 2016;2016:1427849. [PMID: 27403030 DOI: 10.1155/2016/1427849] [Cited by in Crossref: 21] [Cited by in F6Publishing: 29] [Article Influence: 3.5] [Reference Citation Analysis]
16 Yuan R, Zhi Q, Zhao H, Han Y, Gao L, Wang B, Kou Z, Guo Z, He S, Xue X, Hu H. Upregulated expression of miR-106a by DNA hypomethylation plays an oncogenic role in hepatocellular carcinoma. Tumour Biol. 2015;36:3093-3100. [PMID: 25510666 DOI: 10.1007/s13277-014-2945-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
17 Serhal R, Saliba N, Hilal G, Moussa M, Hassan GS, El Atat O, Alaaeddine N. Effect of adipose-derived mesenchymal stem cells on hepatocellular carcinoma: In vitro inhibition of carcinogenesis. World J Gastroenterol 2019; 25(5): 567-583 [PMID: 30774272 DOI: 10.3748/wjg.v25.i5.567] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
18 Fan H, Yi W, Wang C, Wang J. The clinicopathological significance and prognostic value of EMMPRIN overexpression in cancers: evidence from 39 cohort studies. Oncotarget 2017;8:82643-60. [PMID: 29137291 DOI: 10.18632/oncotarget.19740] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
19 Lim J, Singal AG. Surveillance and Diagnosis of Hepatocellular Carcinoma. Clin Liver Dis (Hoboken) 2019;13:2-5. [PMID: 30911378 DOI: 10.1002/cld.761] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
20 Zhao Y, Zhang R, Zhang H, Xie X. Novel Electrochemical Immunoassay for Carcinoembryonic Antigen Using Ferrocenyl Polymer Nanospheres. Analytical Letters 2016;49:2931-42. [DOI: 10.1080/00032719.2016.1167899] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
21 Li J, Chen X, Dai M, Huang S, Chen J, Dai S. Diagnostic accuracy of osteopontin plus alpha-fetoprotein in the hepatocellular carcinoma: A meta-analysis. Clin Res Hepatol Gastroenterol 2017;41:543-53. [PMID: 28291627 DOI: 10.1016/j.clinre.2017.01.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
22 Liu CC, Yang H, Zhang R, Zhao JJ, Hao DJ. Tumour-associated antigens and their anti-cancer applications. Eur J Cancer Care (Engl). 2017;26. [PMID: 26853428 DOI: 10.1111/ecc.12446] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
23 Huang A, Zhang X, Zhou SL, Cao Y, Huang XW, Fan J, Yang XR, Zhou J. Plasma Circulating Cell-free DNA Integrity as a Promising Biomarker for Diagnosis and Surveillance in Patients with Hepatocellular Carcinoma. J Cancer 2016;7:1798-803. [PMID: 27698918 DOI: 10.7150/jca.15618] [Cited by in Crossref: 26] [Cited by in F6Publishing: 32] [Article Influence: 4.3] [Reference Citation Analysis]
24 Yi PS, Zhang M, Zhao JT, Xu MQ. Liver resection for intermediate hepatocellular carcinoma. World J Hepatol 2016; 8(14): 607-615 [PMID: 27190577 DOI: 10.4254/wjh.v8.i14.607] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
25 Osho A, Rich NE, Singal AG. Role of imaging in management of hepatocellular carcinoma: surveillance, diagnosis, and treatment response. Hepatoma Res 2020;6:55. [PMID: 32944652 DOI: 10.20517/2394-5079.2020.42] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
26 Wang W, Cai X, Li Q, Zheng L, Yu X, Zhang H, Wang J. Application of a microfluidic paper-based bioimmunosensor with laser-induced fluorescence detection in the determination of alpha-fetoprotein from serum of hepatopaths. Talanta 2021;221:121660. [DOI: 10.1016/j.talanta.2020.121660] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
27 Shi D, Wu F, Gao F, Qing X, Shao Z. Prognostic value of long non-coding RNA CCAT1 expression in patients with cancer: A meta-analysis. PLoS One 2017;12:e0179346. [PMID: 28594897 DOI: 10.1371/journal.pone.0179346] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
28 Qu Z, Yuan CH, Yin CQ, Guan Q, Chen H, Wang FB. Meta-analysis of the prognostic value of abnormally expressed lncRNAs in hepatocellular carcinoma. Onco Targets Ther 2016;9:5143-52. [PMID: 27574455 DOI: 10.2147/OTT.S108599] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
29 Wang WL, Zheng XL, Zhang ZY, Zhou Y, Hao J, Tang G, Li O, Xiang JX, Wu Z, Wang B. Preoperative γ-glutamyl transpeptidase to platelet ratio (GPR) is an independent prognostic factor for HBV-related hepatocellular carcinoma after curative hepatic resection. Medicine (Baltimore) 2016;95:e4087. [PMID: 27399101 DOI: 10.1097/MD.0000000000004087] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
30 Sun J, Hu T, Chen C, Zhao D, Yang F, Yang X. Fluorescence Immunoassay System via Enzyme-Enabled in Situ Synthesis of Fluorescent Silicon Nanoparticles. Anal Chem 2016;88:9789-95. [DOI: 10.1021/acs.analchem.6b02847] [Cited by in Crossref: 70] [Cited by in F6Publishing: 60] [Article Influence: 11.7] [Reference Citation Analysis]
31 Nowicki TK, Markiet K, Szurowska E. Diagnostic Imaging of Hepatocellular Carcinoma - A Pictorial Essay. Curr Med Imaging Rev 2017;13:140-53. [PMID: 28553196 DOI: 10.2174/1573405612666160720123748] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
32 Song PP, Xia JF, Inagaki Y, Hasegawa K, Sakamoto Y, Kokudo N, Tang W. Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma. World J Gastroenterol 2016; 22(1): 262-274 [PMID: 26755875 DOI: 10.3748/wjg.v22.i1.262] [Cited by in CrossRef: 69] [Cited by in F6Publishing: 61] [Article Influence: 11.5] [Reference Citation Analysis]
33 Wei J, Liu Y, Zhao C. Integrated Analysis of FAM57A Expression and Its Potential Roles in Hepatocellular Carcinoma. Front Oncol 2021;11:719973. [PMID: 34790567 DOI: 10.3389/fonc.2021.719973] [Reference Citation Analysis]
34 Xing S, Kan J, Su A, Liu QD, Wang K, Cai X, Dong J. The prognostic value of major facilitator superfamily domain-containing protein 2A in patients with hepatocellular carcinoma. Aging (Albany NY) 2019;11:8474-83. [PMID: 31584009 DOI: 10.18632/aging.102333] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
35 Iwata T, Kondo Y, Kimura O, Morosawa T, Fujisaka Y, Umetsu T, Kogure T, Inoue J, Nakagome Y, Shimosegawa T. PD-L1+MDSCs are increased in HCC patients and induced by soluble factor in the tumor microenvironment. Sci Rep 2016;6:39296. [PMID: 27966626 DOI: 10.1038/srep39296] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 6.3] [Reference Citation Analysis]
36 Caviglia GP, Abate ML, Petrini E, Gaia S, Rizzetto M, Smedile A. Highly sensitive alpha-fetoprotein, Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxyprothrombin for hepatocellular carcinoma detection: Highly sensitive HCC biomarkers. Hepatol Res 2016;46:E130-5. [DOI: 10.1111/hepr.12544] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
37 Chen J, Huang S, Li I, Lin K, Tsay S. Prognostic association of demographic and clinical factors with the change rates of symptoms and depression among patients with hepatocellular carcinoma. Support Care Cancer 2019;27:4665-74. [DOI: 10.1007/s00520-019-04776-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
38 Fu YP, Yi Y, Huang JL, Jing CY, Sun J, Ni XC, Lu ZF, Cao Y, Zhou J, Fan J, Qiu SJ. Prognostic Nomograms Stratify Survival of Patients with Hepatocellular Carcinoma Without Portal Vein Tumor Thrombosis After Curative Resection. Oncologist 2017;22:561-9. [PMID: 28438885 DOI: 10.1634/theoncologist.2016-0231] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
39 Xu Y, Bu X, Dai C, Shang C. High serum microRNA-122 level is independently associated with higher overall survival rate in hepatocellular carcinoma patients. Tumour Biol. 2015;36:4773-4776. [PMID: 25636448 DOI: 10.1007/s13277-015-3128-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
40 Piratvisuth T, Tanwandee T, Thongsawat S, Sukeepaisarnjaroen W, Esteban JI, Bes M, Köhler B, He Y, Swiatek-de Lange M, Morgenstern D, Chan HL. Multimarker Panels for Detection of Early Stage Hepatocellular Carcinoma: A Prospective, Multicenter, Case-Control Study. Hepatol Commun 2021. [PMID: 34796691 DOI: 10.1002/hep4.1847] [Reference Citation Analysis]
41 Zhou Y, Chai H, Guo L, Dai Z, Lai J, Duan J, Liu Y, Ding Q. Knockdown of CENPW Inhibits Hepatocellular Carcinoma Progression by Inactivating E2F Signaling. Technol Cancer Res Treat 2021;20:15330338211007253. [PMID: 33973496 DOI: 10.1177/15330338211007253] [Reference Citation Analysis]
42 Wang F, Feng Y, Li P, Wang K, Feng L, Liu YF, Huang H, Guo YB, Mao QS, Xue WJ. RASSF10 is an epigenetically inactivated tumor suppressor and independent prognostic factor in hepatocellular carcinoma. Oncotarget 2016;7:4279-97. [PMID: 26701853 DOI: 10.18632/oncotarget.6654] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
43 Zhang Z, Lei B, Chai W, Liu R, Li T. Increased expression of insulin-like growth factor-1 receptor predicts poor prognosis in patients with hepatocellular carcinoma. Medicine (Baltimore) 2019;98:e17680. [PMID: 31689787 DOI: 10.1097/MD.0000000000017680] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
44 Zhang L, Chen J, Gao C, Liu C, Xu K. An efficient model for auxiliary diagnosis of hepatocellular carcinoma based on gene expression programming. Med Biol Eng Comput 2018;56:1771-9. [DOI: 10.1007/s11517-018-1811-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
45 Yang B, Wang S, Xie H, Wang C, Gao X, Rong Y, Liu Z, Lu Y. KIF18B promotes hepatocellular carcinoma progression through activating Wnt/β-catenin-signaling pathway. J Cell Physiol 2020;235:6507-14. [PMID: 32052444 DOI: 10.1002/jcp.29444] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
46 Zheng H, Yang Y, Wang M, Yuan S, Tian T, Han J, Ni J, Wang J, Xing H, Zhou W. Low CDX1 expression predicts a poor prognosis for hepatocellular carcinoma patients after hepatectomy. Surgical Oncology 2016;25:171-7. [DOI: 10.1016/j.suronc.2016.05.026] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
47 Huang A, Zhang X, Zhou SL, Cao Y, Huang XW, Fan J, Yang XR, Zhou J. Detecting Circulating Tumor DNA in Hepatocellular Carcinoma Patients Using Droplet Digital PCR Is Feasible and Reflects Intratumoral Heterogeneity. J Cancer. 2016;7:1907-1914. [PMID: 27698932 DOI: 10.7150/jca.15823] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 8.3] [Reference Citation Analysis]
48 Li Z, Zhou Y, Yang G, He S, Qiu X, Zhang L, Deng Q, Zheng F. Using circular RNA SMARCA5 as a potential novel biomarker for hepatocellular carcinoma. Clinica Chimica Acta 2019;492:37-44. [DOI: 10.1016/j.cca.2019.02.001] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 13.3] [Reference Citation Analysis]
49 Wong RJ, Ahmed A, Gish RG. Elevated alpha-fetoprotein: differential diagnosis - hepatocellular carcinoma and other disorders. Clin Liver Dis. 2015;19:309-323. [PMID: 25921665 DOI: 10.1016/j.cld.2015.01.005] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 7.6] [Reference Citation Analysis]
50 Zhu K, Zhan H, Peng Y, Yang L, Gao Q, Jia H, Dai Z, Tang Z, Fan J, Zhou J. Plasma hsa_circ_0027089 is a diagnostic biomarker for hepatitis B virus-related hepatocellular carcinoma. Carcinogenesis 2020;41:296-302. [PMID: 31535687 DOI: 10.1093/carcin/bgz154] [Cited by in Crossref: 21] [Cited by in F6Publishing: 27] [Article Influence: 10.5] [Reference Citation Analysis]
51 Guo H, Zhou X, Lu Y, Xie L, Chen Q, Keller ET, Liu Q, Zhou Q, Zhang J. Translational progress on tumor biomarkers. Thorac Cancer 2015;6:665-71. [PMID: 26557902 DOI: 10.1111/1759-7714.12294] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
52 Miller-Atkins G, Acevedo-Moreno LA, Grove D, Dweik RA, Tonelli AR, Brown JM, Allende DS, Aucejo F, Rotroff DM. Breath Metabolomics Provides an Accurate and Noninvasive Approach for Screening Cirrhosis, Primary, and Secondary Liver Tumors. Hepatol Commun 2020;4:1041-55. [PMID: 32626836 DOI: 10.1002/hep4.1499] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
53 Wang Y, Wu N, Luo X, Zhang X, Liao Q, Wang J. SOX2OT, a novel tumor-related long non-coding RNA. Biomed Pharmacother 2020;123:109725. [PMID: 31865145 DOI: 10.1016/j.biopha.2019.109725] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
54 Zhang Y, Yang J, Wang J, Chen L, Huang H, Xiong Y, Xie B. Quantification of serum purine metabolites for distinguishing patients with hepatitis B from hepatocellular carcinoma. Bioanalysis 2019;11:1003-13. [PMID: 31218896 DOI: 10.4155/bio-2018-0319] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
55 Liu Y, Zhang Q, Yang X, Li Y, Zhu B, Niu S, Huang Y, Hu Y, Wang X. Effects of various interventions on the occurrence of macrovascular invasion of hepatocellular carcinoma after the baseline serum γ-glutamyltransferase stratification. Onco Targets Ther 2019;12:1671-9. [PMID: 30881022 DOI: 10.2147/OTT.S184302] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
56 Ozgor D, Otan E. HCC and Tumor Biomarkers: Does One Size Fits All? J Gastrointest Cancer 2020;51:1122-6. [PMID: 32827068 DOI: 10.1007/s12029-020-00485-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
57 Sun J, Hu T, Xu X, Wang L, Yang X. A fluorescent ELISA based on the enzyme-triggered synthesis of poly(thymine)-templated copper nanoparticles. Nanoscale 2016;8:16846-50. [DOI: 10.1039/c6nr06446a] [Cited by in Crossref: 32] [Cited by in F6Publishing: 4] [Article Influence: 5.3] [Reference Citation Analysis]
58 Saber MA, MM AbdelHafiz S, Khorshed FE, Aboushousha TS, Hamdy HE, Seleem MI, Soliman AH. Differential Expression of Glypican-3 and Insulin–Like Growth Factor-II mRNAs and Alpha-Fetoprotein and Ki-67 Markers in HCV Related Hepatocellular Carcinomas In Egyptian Patients. Asian Pac J Cancer Prev 2017;18:121-7. [PMID: 28240019 DOI: 10.22034/APJCP.2017.18.1.121] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
59 Zheng C, Liu X, Chen L, Xu Z, Shao J. lncRNAs as prognostic molecular biomarkers in hepatocellular carcinoma: a systematic review and meta-analysis. Oncotarget 2017;8:59638-47. [PMID: 28938667 DOI: 10.18632/oncotarget.19559] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
60 Atiq O, Tiro J, Yopp AC, Muffler A, Marrero JA, Parikh ND, Murphy C, McCallister K, Singal AG. An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis. Hepatology 2017;65:1196-205. [PMID: 27775821 DOI: 10.1002/hep.28895] [Cited by in Crossref: 123] [Cited by in F6Publishing: 114] [Article Influence: 24.6] [Reference Citation Analysis]
61 Grimm D, Lieb J, Weyer V, Vollmar J, Darstein F, Lautem A, Hoppe-Lotichius M, Koch S, Schad A, Schattenberg JM, Wörns MA, Weinmann A, Galle PR, Zimmermann T. Organic Cation Transporter 1 (OCT1) mRNA expression in hepatocellular carcinoma as a biomarker for sorafenib treatment. BMC Cancer 2016;16:94. [PMID: 26872727 DOI: 10.1186/s12885-016-2150-3] [Cited by in Crossref: 23] [Cited by in F6Publishing: 28] [Article Influence: 3.8] [Reference Citation Analysis]
62 Song L, Zhang JG, Zheng L, Feng X, Hou J, Zhang HL, Liu SF. Establishment of rat liver cancer cell lines with different metastatic potential. Sci Rep 2020;10:8329. [PMID: 32433581 DOI: 10.1038/s41598-020-65338-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
63 Liu Y, Feng Y, Wang X, Yang X, Hu Y, Li Y, Zhang Q, Huang Y, Shi K, Ran C, Hou J, Jiang L, Li J, Wang X. SPARC Negatively Correlates With Prognosis After Transarterial Chemoembolization and Facilitates Proliferation and Metastasis of Hepatocellular Carcinoma via ERK/MMP Signaling Pathways. Front Oncol 2020;10:813. [PMID: 32670867 DOI: 10.3389/fonc.2020.00813] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
64 Terzi E, Salvatore V, Negrini G, Piscaglia R. Ongoing challenges in the diagnosis of hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol. 2015;Nov 24; Epub ahead of print. [PMID: 26603785 DOI: 10.1586/17474124.2016.1124758] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
65 Li F, Liu T, Xiao CY, Yu JX, Lu LG, Xu MY. FOXP1 and SPINK1 reflect the risk of cirrhosis progression to HCC with HBV infection. Biomed Pharmacother 2015;72:103-8. [PMID: 26054682 DOI: 10.1016/j.biopha.2015.04.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
66 Cui SX, Yu XF, Qu XJ. Roles and Signaling Pathways of Des-γ-Carboxyprothrombin in the Progression of Hepatocellular Carcinoma. Cancer Invest 2016;34:459-64. [PMID: 27673353 DOI: 10.1080/07357907.2016.1227445] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]